Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (680)	10/15/1999 1:04:00 AM
From: JDGarza	Read Replies (1) \| Respond to of 798

Tom, I bought more at 20 ... and was curious whether you added to your position today?

To: OldAIMGuy who wrote (680)	10/20/1999 11:13:00 AM
From: Lighthouse	Read Replies (1) \| Respond to of 798

Greetings! I do not mean to intrude. Several Wall Street firms have moved their target growth rate for the overall stent market to near zero for the time being. That is a big change and there are always fears that with a mature market that pricing will erode to European levels. So far no evidence to support this fear, but it is out there. At the same time I have read two reports of firms moving stent market share assumptions for BSX down by apx. 200 basis points. New stent product rollout looks relatively weak vis-a-vis GDT and some JNJ models. Throw in a crappy market, past BSX blow ups, no major executive hires to round out Tobin, Y2K, St Louis Rams undefeated and no one wants to talk about this story. Nonetheless I am in.